Transcranial magnetic stimulation

Transcranial magnetic stimulation
Transcranial magnetic stimulation
(schematic diagram)
SpecialtyPsychiatry, neurology
MeSHD050781

Transcranial magnetic stimulation (TMS) is a noninvasive neurostimulation technique in which a changing magnetic field is used to induce an electric current in a targeted area of the brain through electromagnetic induction. A device called a stimulator generates electric pulses that are delivered to a magnetic coil placed against the scalp. The resulting magnetic field penetrates the skull and induces a secondary electric current in the underlying brain tissue, modulating neural activity.[1][2]

Repetitive transcranial magnetic stimulation (rTMS) is a safe, effective, and FDA-approved treatment for major depressive disorder (approved in 2008), chronic pain (2013), and obsessive-compulsive disorder (2018).[3] It has strong evidence for certain neurological and psychiatric conditions—especially depression (with a large effect size), neuropathic pain, and stroke recovery—and emerging advancements like iTBS and image-guided targeting may improve its efficacy and efficiency.[4][5]

Adverse effects of TMS appear rare and include fainting and seizure, which occur in roughly 0.1% of patients and are usually attributable to administration error.[6]

  1. ^ "Transcranial magnetic stimulation for treating and preventing migraine". National Institute for Health and Care Excellence. January 2014.
  2. ^ Miller, Michael Craig (July 26, 2012). "Magnetic stimulation: a new approach to treating depression?". Harvard Health Publishing.
  3. ^ Mann, Sukhmanjeet Kaur; Malhi, Narpinder K. (6 March 2023). "Repetitive Transcranial Magnetic Stimulation (rTMS)". StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved 1 May 2025.
  4. ^ Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, et al. (February 2020). "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018)". Clin Neurophysiol. 131 (2): 474–528. doi:10.1016/j.clinph.2019.11.002. hdl:10362/147799. PMID 31901449.
  5. ^ McClintock, S. M.; Carpenter, L. L.; Downar, J.; et al. (2025). "Consensus review and considerations on TMS to treat depression". *Journal of the Neurological Sciences*. 459: 121579. doi:[10.1016/j.jns.2024.121579](https://doi.org/10.1016/j.jns.2024.121579).
  6. ^ Rossi; et al. (January 2021). "Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines". Clinical Neurophysiology. 132 (1): 269–306. doi:10.1016/j.clinph.2020.10.003. PMC 9094636. PMID 33243615. S2CID 225049093.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search